



**AUSTRALIAN
FEDERATION OF AIDS
ORGANISATIONS**
ABN 91 708 310 631

PO Box 51
Newtown NSW
2042 AUSTRALIA

Tel: +61 2 9557-9399
Fax +61 2 9557-9867
Email: afao@afao.org.au
Web: www.afao.org.au

7 June 2017

PBAC Secretariat
Department of Health and Ageing
GPO Box 9848
CANBERRA ACT 2601

Dear PBAC Secretariat,

Re: Hepatitis Australia's Submission on AbbVie Application for glecaprevir 100mg + pibrentasvir 40mg

I write on behalf of the Australian Federation of AIDS Organisations (AFAO) to provide this letter in support of Hepatitis Australia's submission.

As the peak national organisation for Australia's community HIV response, AFAO is recognised nationally and globally for the leadership, policy expertise, coordination and support we provide. Through advocacy, policy and health promotion, we champion awareness, understanding and proactivity around HIV prevention, education, support and research. AFAO provides a voice for communities affected by HIV and leads the national conversation on HIV. AFAO is particularly concerned to ensure communities affected by HIV are able to gain access to important new medicines and medical devices as soon as possible.

AFAO works closely with Hepatitis Australia in recognition of the disproportionate burden of hepatitis C experiences by our communities.

I have had an opportunity to review the comments submitted by Hepatitis Australia. AFAO fully endorses the comments from Hepatitis Australia, including its view that the new wave of pan-genotypic medicines introduces a significant opportunity to enhance prescribing of direct-acting antivirals by general practitioners.

Please do not hesitate to contact me if you would like to discuss this further or if I can provide further information in support of the application. I can be contacted on 02 8568 1100 or at Darryl.O'Donnell@afao.org.au.

Yours sincerely,

Adj A/Prof Darryl O'Donnell
Chief Executive Officer